Subject(s)
Alitretinoin/administration & dosage , Dermatologic Agents/administration & dosage , Keratoderma, Palmoplantar/drug therapy , Adaptor Proteins, Vesicular Transport/genetics , Administration, Oral , Adult , Aged , Aged, 80 and over , Alitretinoin/adverse effects , Cohort Studies , DNA Mutational Analysis , Dermatologic Agents/adverse effects , Dose-Response Relationship, Drug , Drug Administration Schedule , Female , Humans , Keratoderma, Palmoplantar/diagnosis , Keratoderma, Palmoplantar/genetics , Male , Middle Aged , Mutation , Treatment OutcomeABSTRACT
Genomic samples of non-model organisms are becoming increasingly important in a broad range of studies from developmental biology, biodiversity analyses, to conservation. Genomic sample definition, description, quality, voucher information and metadata all need to be digitized and disseminated across scientific communities. This information needs to be concise and consistent in today's ever-increasing bioinformatic era, for complementary data aggregators to easily map databases to one another. In order to facilitate exchange of information on genomic samples and their derived data, the Global Genome Biodiversity Network (GGBN) Data Standard is intended to provide a platform based on a documented agreement to promote the efficient sharing and usage of genomic sample material and associated specimen information in a consistent way. The new data standard presented here build upon existing standards commonly used within the community extending them with the capability to exchange data on tissue, environmental and DNA sample as well as sequences. The GGBN Data Standard will reveal and democratize the hidden contents of biodiversity biobanks, for the convenience of everyone in the wider biobanking community. Technical tools exist for data providers to easily map their databases to the standard.Database URL: http://terms.tdwg.org/wiki/GGBN_Data_Standard.
Subject(s)
Biodiversity , Databases, Nucleic Acid , GenomeABSTRACT
Perovskite materials are now an important class of materials in the application areas of photovoltaics and photocatalysis. Inorganic perovskites such as BiFeO3 (BFO) are promising photocatalyst materials with visible light activity and inherent stability. Here we report the large area sol-gel synthesis of BFO films for solar stimulated water photo oxidation. By modifying the sol-gel synthesis process we have produced a perovskite material that has p-type behaviour and a flat band potential of â¼1.15 V (versus NHE). The photocathode produces a density of -0.004 mA cm(-2) at 0 V versus NHE under AM1.5 G illumination. We further show that 0.6 µmol h(-1) of O2 was produced at an external bias of -0.5 V versus Ag/AgCl. The addition of a non-percolating conducting network of Ag increases the photocurrent to -0.07 mA cm(-2) at 0 V versus NHE (at 2% Ag loading) with an increase to 2.7 µmol h(-1) for O2 production. We attribute the enhancement in photoelectrochemical performance to increased light absorption due light scattering by the incorporated Ag particles, improved charge transfer kinetics at the Ag/BFO interface and reduced over potential losses. We support these claims by an observed shift in flat band and onset potentials after Ag modification through UV-vis spectroscopy, Mott-Schottky plots and j-v curve analysis.
ABSTRACT
BACKGROUND AND OBJECTIVES: Plasma exchange (PE) and immunoadsorption with the Immusorba TR-350 column (IA) are used to remove autoantibodies from plasma in acute neurological autoimmune disorders. The impact of IA on coagulation and on low molecular weight heparin (LMWH) levels in comparison with PE was investigated. PATIENTS AND METHODS: In five patients with neurological autoimmune disorders, coagulation parameters (global tests, coagulation factors) were measured before and after PE or IA (Part A). In five other patients under anticoagulation with LMWH, anti-Xa activity and global tests were measured before and after the treatments (Part B). RESULTS: After PE, coagulation factors were significantly reduced by 50-70%. After IA, a distinct reduction was observed for fibrinogen, but not for antithrombin and most of the other coagulation factors. Anti-Xa activity was reduced after PE (from 0.57 ± 0·10 to 0.13 ± 0.05 IU/ml) and almost unchanged after IA. CONCLUSION: It is advisable to discontinue or to reduce LMWH doses and to monitor coagulation parameters and anti-Xa activity after PE or IA to decide about further LMWH dosing.
